WO2009036768A3 - Diagnosing potential weight gain in a subject - Google Patents

Diagnosing potential weight gain in a subject Download PDF

Info

Publication number
WO2009036768A3
WO2009036768A3 PCT/DK2008/050227 DK2008050227W WO2009036768A3 WO 2009036768 A3 WO2009036768 A3 WO 2009036768A3 DK 2008050227 W DK2008050227 W DK 2008050227W WO 2009036768 A3 WO2009036768 A3 WO 2009036768A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
present
invention further
further relates
weight gain
Prior art date
Application number
PCT/DK2008/050227
Other languages
French (fr)
Other versions
WO2009036768A2 (en
Inventor
Benny Bang-Andersen
John Nicholas Pearson
Original Assignee
Lundbeck & Co As H
Benny Bang-Andersen
John Nicholas Pearson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H, Benny Bang-Andersen, John Nicholas Pearson filed Critical Lundbeck & Co As H
Publication of WO2009036768A2 publication Critical patent/WO2009036768A2/en
Publication of WO2009036768A3 publication Critical patent/WO2009036768A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Abstract

The present invention relates to a method for diagnosing or prognosing potential metabolic syndrome in a subject. The present invention further relates to a method for diagnosing or prognosing potential metabolic syndrome in a subject, which can be induced by medication. The present invention further relates to use of an agent in the manufacture of a medicament for treating a disorder or a disease in a subject. The present invention further relates to an agent for use in a method for treating a disorder or a disease in a subject. The present invention further relates to a method for treating a disorder or a disease in a subject comprising administering a therapeutically effective amount of an agent to a subject. The present invention further relates to a method for identifying an anti-psychotic compound.
PCT/DK2008/050227 2007-09-19 2008-09-18 Diagnosing potential weight gain in a subject WO2009036768A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97346607P 2007-09-19 2007-09-19
DKPA200701353 2007-09-19
DKPA200701353 2007-09-19
US60/973,466 2007-09-19

Publications (2)

Publication Number Publication Date
WO2009036768A2 WO2009036768A2 (en) 2009-03-26
WO2009036768A3 true WO2009036768A3 (en) 2009-08-20

Family

ID=40291125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050227 WO2009036768A2 (en) 2007-09-19 2008-09-18 Diagnosing potential weight gain in a subject

Country Status (1)

Country Link
WO (1) WO2009036768A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102038462B1 (en) 2011-12-15 2019-10-31 노파르티스 아게 Use of inhibitors of the activity or function of PI3K
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
WO2016128348A1 (en) * 2015-02-13 2016-08-18 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104239A1 (en) * 2002-06-05 2003-12-18 Ivax Corporation Compound for the treatment of cns disorders
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
US20070154576A1 (en) * 2005-12-09 2007-07-05 Tripp Matthew L Protein kinase modulation by hops and Acacia products
WO2007129113A2 (en) * 2006-05-02 2007-11-15 University Of Southampton Phenotype prediction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104239A1 (en) * 2002-06-05 2003-12-18 Ivax Corporation Compound for the treatment of cns disorders
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
US20070154576A1 (en) * 2005-12-09 2007-07-05 Tripp Matthew L Protein kinase modulation by hops and Acacia products
WO2007129113A2 (en) * 2006-05-02 2007-11-15 University Of Southampton Phenotype prediction

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AUBIN D ET AL: "Phosphoinositide 3-kinase is required for human adipocyte differentiation in culture", INTERNATIONAL JOURNAL OF OBESITY, vol. 29, no. 8, August 2005 (2005-08-01), pages 1006 - 1009, XP002513344, ISSN: 0307-0565 *
CHAUSSADE CLAIRE ET AL: "Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling", BIOCHEMICAL JOURNAL, vol. 404, no. Part 3, June 2007 (2007-06-01), pages 449 - 458, XP002513345, ISSN: 0264-6021(print) 1470-8728(ele *
ENGL J ET AL: "Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells", December 2005, MOLECULAR PSYCHIATRY, VOL. 10, NR. 12, PAGE(S) 1089-1096, ISSN: 1359-4184, XP002534587 *
GRAY ALEXANDER ET AL: "Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts.", 15 February 2003, ANALYTICAL BIOCHEMISTRY, VOL. 313, NR. 2, PAGE(S) 234-245, ISSN: 0003-2697, XP002513347 *
HENRY CHANTAL ET AL: "Olanzapine-induced mania in bipolar disorders", JOURNAL OF PSYCHIATRY AND NEUROSCIENCE, vol. 27, no. 3, May 2002 (2002-05-01), pages 200 - 201, XP002534585, ISSN: 1180-4882 *
LU XIAO-HONG ET AL: "Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38", BRAIN RESEARCH, vol. 1011, no. 1, 11 June 2004 (2004-06-11), pages 58 - 68, XP002534586, ISSN: 0006-8993 *
OKKENHAUG KLAUS ET AL: "Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice", 9 August 2002, SCIENCE (WASHINGTON D C), VOL. 297, NR. 5583, PAGE(S) 1031-1034, ISSN: 0036-8075, XP002513346 *
ROTHSCHILD A J ET AL: "OLANZAPINE RESPONSE IN PSYCHOTIC DEPRESSION", JOURNAL OF CLINICAL PSYCHIATRY,, vol. 60, no. 2, 1 February 1999 (1999-02-01), pages 116 - 118, XP008016700, ISSN: 0160-6689 *

Also Published As

Publication number Publication date
WO2009036768A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EP2512479A4 (en) Methods and compositions for treating peripheral vascular disease
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2007133731A3 (en) Creatine-ligand compounds and methods of use thereof
WO2007076295A3 (en) Nanoclusters for delivery of therapeutics
MX2011010964A (en) 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2.
MX2012014934A (en) Cyclohexyl-azetidinyl antagonists of ccr2.
WO2008050329A3 (en) Novel sirnas and methods of use thereof
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
UA103614C2 (en) Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody
BR112012012903A2 (en) spiropiperidine compounds
WO2007092936A3 (en) Method to treat gastric lesions
AR065392A1 (en) METHODS FOR TREATMENT BY INHALATION OF A DISEASE OR RESPIRATORY STATE
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
EA201070477A1 (en) TRANS-CLOMIFEN FOR THE TREATMENT OF METABOLIC SYNDROME
WO2009002808A3 (en) Quinazolinone compounds and methods of use thereof
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2011010919A (en) 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2.
MX2011010963A (en) 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08801403

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08801403

Country of ref document: EP

Kind code of ref document: A2